Semtech Analyst Day Review
Semtech raised Q3 guidance and targets $3.2 billion of fiscal 2030 revenue, excluding upside from its AI data-center optical and copper interconnect businesses.
Semtech raised Q3 guidance and targets $3.2 billion of fiscal 2030 revenue, excluding upside from its AI data-center optical and copper interconnect businesses.
A fun trade I've had in is arbing convertible preferreds. Long $PCGPRX short $PCG, long $QXOPRB short $QXO. Trading below the convertible price while pocketing a nice dividend with cheap financing.
$BMRN up premarket on settlement agreement. I continue to like/own. https://t.co/a6WZ9ksaeH
A formal phase-two strategic review is now underway. Transaction comps imply 10–14x EBITDA versus $PBI’s much lower multiple. Greystone’s conservative value is in the mid-$20s versus ~$16.50, with a deal offering further upside.
AI could pressure $DOX revenue, but also lower delivery costs. If the embedded managed-services franchise holds up, modest growth and buybacks could drive attractive returns without a heroic recovery. The key risk is AI savings flowing to customers rather than shareholders.
9/ $PBI pitch by @GreystoneCap Pitney Bowes owns a sticky postage-meter installed base and the only national-scale US presort network. The market still treats it as a terminally declining mailing-equipment business.
8/ $DOX pitch by Rewey Asset Management ~7x FCF for mission-critical telecom software priced like an AI casualty. Roughly two-thirds of Amdocs’ revenue comes from long-term managed services built around proprietary billing and customer-care systems that are risky to replace.
5/ $FOUR pitch by Emeth Value Capital Shift4 is an end-to-end payments platform dominating attractive verticals. It is the #2 US restaurant POS provider, serves ~40% of US hotels and processes payments for 75%+ of professional sports venues.
Steve Eisman examines AI data-center debt, CoreWeave's tech correction and agentic AI's effect on banks as earnings season begins.
CoreWeave’s debt and equity price action is framed as a wake-up call for investors amid a broader market discussion.
PesoRama will reach 54 JOi Dollar Plus stores by November after raising C$28.4 million, funding more than 50 additional Mexican store…
Modine, soon Modexus Solutions, has a $4 billion hyperscaler cooling contract but must ramp factory output and restore margins as data…
AppLovin rebuilt its ad model with AXON 2.0, lifting LTM revenue to about $7 billion and margins to 77% as Unity competition threatens…
Brookfield Asset Management's fee revenue rose 16.2% and distributable earnings 15.8%, but its 18% five-year target relies on AI-led growth…
Marvell is positioning networking, optical connectivity and server-management chips as AI data centers link GPUs, custom accelerators and…
AeroVironment's $465M LOCUST laser award and earnings beat support its 2027 growth outlook despite government budget uncertainty.
Constellation Brands trades near $127 at roughly 11x next-twelve-month EV/EBIT, with recent business results offsetting concerns over…
Transocean’s Valaris merger clears regulators, creating a 68-rig offshore driller controlling four in 10 global drillships.
SPHR · long Sphere Entertainment is shifting from construction and startup spending to a high-margin, cash-generative venue-operator model, with…
October 2026 market commentary covers SOLS’s cancelled merger, a hypothetical Starbucks-Chipotle deal, Russell 2000 weakness and AI…
CoreWeave faces fresh skepticism as another AI trade selloff collides with bullish defenses of the company.
Ari Emanuel discusses AI’s impact on Hollywood, live events, social networks and the future of advertising.
RTX’s $289 billion backlog, including $119 billion in defense, supports growth from defense contracts and commercial aerospace aftermarket…
Peabody Energy’s recovery case hinges on Centurion, coal-market leverage, capital allocation and balance-sheet strength amid commodity…
Applied Materials leads wafer-fab deposition and ranks third in etch, positioning it for tougher 3D chip manufacturing as investors weigh a…
First Tracks Biotherapeutics’ ANB033 posted stronger Phase 1b celiac efficacy than Teva’s IL-15 inhibitor, with $168 million funding…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.